HomeCompareTBPMF vs CHD

TBPMF vs CHD: Dividend Comparison 2026

TBPMF yields 222222.22% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBPMF wins by $1.4076447531278624e+30M in total portfolio value
10 years
TBPMF
TBPMF
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full TBPMF calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — TBPMF vs CHD

📍 TBPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBPMFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBPMF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBPMF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBPMF
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, TBPMF beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBPMF + CHD for your $10,000?

TBPMF: 50%CHD: 50%
100% CHD50/50100% TBPMF
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

TBPMF
No analyst data
Altman Z
-75.5
Piotroski
2/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBPMF buys
0
CHD buys
11
PoliticianChamberTickerTypeAmountDate
Richard W. Allen🏢 House$CHD▼ Sell$15,001 - $50,0002025-10-10
Ro Khanna🏢 House$CHD▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-08-04
Ro Khanna🏢 House$CHD▲ Buy$1,000 - $15,0002025-08-04
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-06-17
Jonathan Jackson🏢 House$CHD▼ Sell$15,001 - $50,0002025-05-14
Jonathan Jackson🏢 House$CHD▼ Sell$1,001 - $15,0002025-05-05
Jonathan Jackson🏢 House$CHD▲ Buy$1,001 - $15,0002025-04-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBPMFCHD
Forward yield222222.22%1.28%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$1.4076447531278624e+30M$26.4K
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00$1,302.64
Total dividends collected$1.4075632434891558e+30M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: TBPMF vs CHD ($10,000, DRIP)

YearTBPMF PortfolioTBPMF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$22,232,922$22,222,222.22$10,857$157.30+$22.22MTBPMF
2$46,198,082,523$46,174,293,296.41$11,814$196.49+$46198.07MTBPMF
3$89,718,752,943,223$89,669,320,994,923.30$12,887$245.97+$89718752.93MTBPMF
4$162,845,393,609,755,680$162,749,394,544,106,430.00$14,097$308.68+$162845393609.74MTBPMF
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$15,473$388.49+$276249735879778.50MTBPMF
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$17,046$490.55+$437989462258048512.00MTBPMF
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$18,861$621.76+$649026142700674875392.00MTBPMF
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$20,973$791.47+$8.988741531797941e+23MTBPMF
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$23,454$1,012.51+$1.1635238864746333e+27MTBPMF
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$26,398$1,302.64+$1.4076447531278624e+30MTBPMF

TBPMF vs CHD: Complete Analysis 2026

TBPMFStock

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Full TBPMF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this TBPMF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBPMF vs SCHDTBPMF vs JEPITBPMF vs OTBPMF vs KOTBPMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.